CA2246027A1 - Derives de benzylamidine avec activite de fixation provenant des recepteurs de la serotonine - Google Patents

Derives de benzylamidine avec activite de fixation provenant des recepteurs de la serotonine Download PDF

Info

Publication number: CA2246027A1
Authority: CA; Canada
Prior art keywords: methyl; butyl; dihydro; imidazole; formula
Prior art date: 1998-08-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2246027

Other languages

English (en)

Inventor

Richard A. Glennon

Ho Law

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allelix Biopharmaceuticals Inc

Virginia Commonwealth University

Original Assignee

Allelix Biopharmaceuticals Inc

Virginia Commonwealth University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-27

Filing date

1998-08-27

Publication date

2000-02-27

1998-08-27 Application filed by Allelix Biopharmaceuticals Inc, Virginia Commonwealth University filed Critical Allelix Biopharmaceuticals Inc

1998-08-27 Priority to CA 2246027 priority Critical patent/CA2246027A1/fr

2000-02-27 Publication of CA2246027A1 publication Critical patent/CA2246027A1/fr

Status Abandoned legal-status Critical Current

Links

230000027455 binding Effects 0.000 title abstract description 12
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title abstract description 9
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 title abstract description 8
150000001875 compounds Chemical class 0.000 claims abstract description 101
150000003839 salts Chemical class 0.000 claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 9
239000012453 solvate Substances 0.000 claims abstract description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 8
208000019695 Migraine disease Diseases 0.000 claims abstract description 7
125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 7
150000004677 hydrates Chemical class 0.000 claims abstract description 7
206010027599 migraine Diseases 0.000 claims abstract description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
125000002947 alkylene group Chemical group 0.000 claims abstract description 4
125000001624 naphthyl group Chemical group 0.000 claims abstract description 4
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 12
125000001475 halogen functional group Chemical group 0.000 claims abstract 6
102000005962 receptors Human genes 0.000 claims description 23
108020003175 receptors Proteins 0.000 claims description 23
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
JLVBPZLGXWLQKB-UHFFFAOYSA-N 2-[(4-tert-butyl-2-methylphenyl)methyl]-4,5-dihydro-1h-imidazole Chemical compound CC1=CC(C(C)(C)C)=CC=C1CC1=NCCN1 JLVBPZLGXWLQKB-UHFFFAOYSA-N 0.000 claims description 9
-1 bromo, t-butyl Chemical group 0.000 claims description 9
MYZPKVPIILDSSN-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCCN1 MYZPKVPIILDSSN-UHFFFAOYSA-N 0.000 claims description 8
ZKSKJIUTPTZSEQ-UHFFFAOYSA-N 2-(4-tert-butyl-2,6-dimethylphenyl)ethanimidamide Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC(N)=N ZKSKJIUTPTZSEQ-UHFFFAOYSA-N 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
PQQRKPXQTFWJHH-UHFFFAOYSA-N 1-benzyl-2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydroimidazole Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1CC1=CC=CC=C1 PQQRKPXQTFWJHH-UHFFFAOYSA-N 0.000 claims description 6
NTSMKZTVZAMTDB-UHFFFAOYSA-N 2-[(2,6-dimethyl-4-propan-2-ylphenyl)methyl]-4,5-dihydro-1h-imidazole Chemical compound CC1=CC(C(C)C)=CC(C)=C1CC1=NCCN1 NTSMKZTVZAMTDB-UHFFFAOYSA-N 0.000 claims description 6
XWSXHGJVQZINIK-UHFFFAOYSA-N 2-[(4-bromo-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazole Chemical compound CC1=CC(Br)=CC(C)=C1CC1=NCCN1 XWSXHGJVQZINIK-UHFFFAOYSA-N 0.000 claims description 6
YWMWOFSCNNTOND-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-1-methyl-4,5-dihydroimidazole Chemical compound CN1CCN=C1CC1=C(C)C=C(C(C)(C)C)C=C1C YWMWOFSCNNTOND-UHFFFAOYSA-N 0.000 claims description 6
HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
DUHARNKZLBMPBS-UHFFFAOYSA-N 2-[(2,4,6-trimethylphenyl)methyl]-4,5-dihydro-1h-imidazole Chemical compound CC1=CC(C)=CC(C)=C1CC1=NCCN1 DUHARNKZLBMPBS-UHFFFAOYSA-N 0.000 claims description 3
CTTYEEFCHQSOQS-UHFFFAOYSA-N 2-[(4-propan-2-ylphenyl)methyl]-4,5-dihydro-1h-imidazole Chemical compound C1=CC(C(C)C)=CC=C1CC1=NCCN1 CTTYEEFCHQSOQS-UHFFFAOYSA-N 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
VIXRKFBKWOHVBR-UHFFFAOYSA-N 2-(naphthalen-2-ylmethyl)-4,5-dihydro-1h-imidazole Chemical compound C=1C=C2C=CC=CC2=CC=1CC1=NCCN1 VIXRKFBKWOHVBR-UHFFFAOYSA-N 0.000 claims description 2
239000000018 receptor agonist Substances 0.000 claims description 2
229940044601 receptor agonist Drugs 0.000 claims description 2
102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 claims 3
101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 claims 3
238000011282 treatment Methods 0.000 abstract description 7
239000003814 drug Substances 0.000 abstract description 4
230000000638 stimulation Effects 0.000 abstract description 3
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 96
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
239000000243 solution Substances 0.000 description 29
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
229910052799 carbon Inorganic materials 0.000 description 18
239000000203 mixture Substances 0.000 description 17
239000007787 solid Substances 0.000 description 15
239000002904 solvent Substances 0.000 description 14
239000003153 chemical reaction reagent Substances 0.000 description 12
239000003446 ligand Substances 0.000 description 11
239000003921 oil Substances 0.000 description 11
235000019198 oils Nutrition 0.000 description 11
125000000217 alkyl group Chemical group 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
238000003756 stirring Methods 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
230000000694 effects Effects 0.000 description 7
125000005843 halogen group Chemical group 0.000 description 7
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 7
229960003708 sumatriptan Drugs 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000012458 free base Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
229940076279 serotonin Drugs 0.000 description 6
239000000725 suspension Substances 0.000 description 6
ZUXNULGHCOXCFL-UHFFFAOYSA-N 2-(4-tert-butyl-2,6-dimethylphenyl)acetonitrile Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC#N ZUXNULGHCOXCFL-UHFFFAOYSA-N 0.000 description 5
239000013078 crystal Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
CSRFNEOWONSYED-UHFFFAOYSA-N (2,6-dimethyl-4-propan-2-ylphenyl)methanol Chemical compound CC(C)C1=CC(C)=C(CO)C(C)=C1 CSRFNEOWONSYED-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000008602 contraction Effects 0.000 description 4
238000001816 cooling Methods 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
YAQVYVOMFYNESZ-UHFFFAOYSA-N (4-bromo-2,6-dimethylphenyl)methanol Chemical compound CC1=CC(Br)=CC(C)=C1CO YAQVYVOMFYNESZ-UHFFFAOYSA-N 0.000 description 3
SDKQOGSGNPGPRN-UHFFFAOYSA-N 2-(2,4,6-trimethylphenyl)acetonitrile Chemical compound CC1=CC(C)=C(CC#N)C(C)=C1 SDKQOGSGNPGPRN-UHFFFAOYSA-N 0.000 description 3
DEAWANMYDBXAKF-UHFFFAOYSA-N 2-(2,6-dimethyl-4-propan-2-ylphenyl)acetonitrile Chemical compound CC(C)C1=CC(C)=C(CC#N)C(C)=C1 DEAWANMYDBXAKF-UHFFFAOYSA-N 0.000 description 3
PYZHIISAQAGNHD-UHFFFAOYSA-N 2-(4-bromo-2,6-dimethylphenyl)acetonitrile Chemical compound CC1=CC(Br)=CC(C)=C1CC#N PYZHIISAQAGNHD-UHFFFAOYSA-N 0.000 description 3
LPZSCLZQMVJBJH-UHFFFAOYSA-N 2-(4-tert-butyl-2-methylphenyl)acetonitrile Chemical compound CC1=CC(C(C)(C)C)=CC=C1CC#N LPZSCLZQMVJBJH-UHFFFAOYSA-N 0.000 description 3
QKJPXROEIJPNHG-UHFFFAOYSA-N 2-(4-tert-butylphenyl)acetonitrile Chemical compound CC(C)(C)C1=CC=C(CC#N)C=C1 QKJPXROEIJPNHG-UHFFFAOYSA-N 0.000 description 3
BTUQATNWCHVBGF-UHFFFAOYSA-N 2-(chloromethyl)-1,3-dimethyl-5-propan-2-ylbenzene Chemical compound CC(C)C1=CC(C)=C(CCl)C(C)=C1 BTUQATNWCHVBGF-UHFFFAOYSA-N 0.000 description 3
DDMGSGAAOLZOBB-UHFFFAOYSA-N 4-tert-butyl-1-(chloromethyl)-2-methylbenzene Chemical compound CC1=CC(C(C)(C)C)=CC=C1CCl DDMGSGAAOLZOBB-UHFFFAOYSA-N 0.000 description 3
BLXADSLLHBDNNI-UHFFFAOYSA-N 5-bromo-2-(chloromethyl)-1,3-dimethylbenzene Chemical compound CC1=CC(Br)=CC(C)=C1CCl BLXADSLLHBDNNI-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229930040373 Paraformaldehyde Natural products 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
238000003556 assay Methods 0.000 description 3
244000309464 bull Species 0.000 description 3
239000002775 capsule Substances 0.000 description 3
235000011167 hydrochloric acid Nutrition 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
SUSQOBVLVYHIEX-UHFFFAOYSA-N o-phenylene-diaceto-nitrile Natural products N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 3
229920002866 paraformaldehyde Polymers 0.000 description 3
235000011056 potassium acetate Nutrition 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000010992 reflux Methods 0.000 description 3
210000003752 saphenous vein Anatomy 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000004479 aerosol dispenser Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000000969 carrier Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000012954 diazonium Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000006196 drop Substances 0.000 description 2
CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000003380 propellant Substances 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
QZNQSIHCDAGZIA-UHFFFAOYSA-N 1-(bromomethyl)-4-tert-butylbenzene Chemical compound CC(C)(C)C1=CC=C(CBr)C=C1 QZNQSIHCDAGZIA-UHFFFAOYSA-N 0.000 description 1
BKLBSKOIVDBFEJ-UHFFFAOYSA-N 1-benzyl-2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydroimidazole;hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1CC1=CC=CC=C1 BKLBSKOIVDBFEJ-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
AJQQOAYOYHVFEY-UHFFFAOYSA-N 2,6-dimethyl-4-propan-2-ylbenzaldehyde Chemical compound CC(C)C1=CC(C)=C(C=O)C(C)=C1 AJQQOAYOYHVFEY-UHFFFAOYSA-N 0.000 description 1
YHHUHIAZGUNKFO-UHFFFAOYSA-N 2-(4-propan-2-ylphenyl)acetamide;hydrochloride Chemical compound Cl.CC(C)C1=CC=C(CC(O)=N)C=C1 YHHUHIAZGUNKFO-UHFFFAOYSA-N 0.000 description 1
RIPHZOPMCRSGSI-UHFFFAOYSA-N 2-(4-propan-2-ylphenyl)acetonitrile Chemical compound CC(C)C1=CC=C(CC#N)C=C1 RIPHZOPMCRSGSI-UHFFFAOYSA-N 0.000 description 1
LAYONLPJVOPBIW-UHFFFAOYSA-N 2-(4-tert-butyl-2,6-dimethylphenyl)acetamide Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC(N)=O LAYONLPJVOPBIW-UHFFFAOYSA-N 0.000 description 1
UNRGEIXQCZHICP-UHFFFAOYSA-N 2-(chloromethyl)-1,3,5-trimethylbenzene Chemical compound CC1=CC(C)=C(CCl)C(C)=C1 UNRGEIXQCZHICP-UHFFFAOYSA-N 0.000 description 1
UJPYMIOQGFLTEG-UHFFFAOYSA-N 2-(naphthalen-2-ylmethyl)-4,5-dihydro-1h-imidazole;hydrochloride Chemical compound Cl.C=1C=C2C=CC=CC2=CC=1CC1=NCCN1 UJPYMIOQGFLTEG-UHFFFAOYSA-N 0.000 description 1
PPDOMMDYAGCCGF-UHFFFAOYSA-N 2-[(2,4,6-trimethylphenyl)methyl]-4,5-dihydro-1h-imidazole;hydrochloride Chemical compound Cl.CC1=CC(C)=CC(C)=C1CC1=NCCN1 PPDOMMDYAGCCGF-UHFFFAOYSA-N 0.000 description 1
TWISFHHFIMNUFN-UHFFFAOYSA-N 2-[(2,6-dimethyl-4-propan-2-ylphenyl)methyl]-4,5-dihydro-1h-imidazole;hydrochloride Chemical compound Cl.CC1=CC(C(C)C)=CC(C)=C1CC1=NCCN1 TWISFHHFIMNUFN-UHFFFAOYSA-N 0.000 description 1
XUZRTLOUOPMCLH-UHFFFAOYSA-N 2-[(4-bromo-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazole;hydrochloride Chemical compound Cl.CC1=CC(Br)=CC(C)=C1CC1=NCCN1 XUZRTLOUOPMCLH-UHFFFAOYSA-N 0.000 description 1
JMTHJPNWACIGNH-UHFFFAOYSA-N 2-[(4-propan-2-ylphenyl)methyl]-4,5-dihydro-1h-imidazole;hydrochloride Chemical compound Cl.C1=CC(C(C)C)=CC=C1CC1=NCCN1 JMTHJPNWACIGNH-UHFFFAOYSA-N 0.000 description 1
UBDDETQJXQLHBO-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-1,4,5,6-tetrahydropyrimidine;hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCCN1 UBDDETQJXQLHBO-UHFFFAOYSA-N 0.000 description 1
BDDIFFLPFBGBPO-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-1-methyl-4,5-dihydroimidazole;hydrochloride Chemical compound Cl.CN1CCN=C1CC1=C(C)C=C(C(C)(C)C)C=C1C BDDIFFLPFBGBPO-UHFFFAOYSA-N 0.000 description 1
YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 description 1
QBZSMNUSFMPRHJ-UHFFFAOYSA-N 2-[(4-tert-butyl-2-methylphenyl)methyl]-4,5-dihydro-1h-imidazole;hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=CC=C1CC1=NCCN1 QBZSMNUSFMPRHJ-UHFFFAOYSA-N 0.000 description 1
LPCWDVLDJVZIHA-UHFFFAOYSA-N 2-naphthalen-2-ylacetonitrile Chemical compound C1=CC=CC2=CC(CC#N)=CC=C21 LPCWDVLDJVZIHA-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
JFRPWJDOGGLZFS-UHFFFAOYSA-N 4-bromo-2,6-dimethylbenzaldehyde Chemical compound CC1=CC(Br)=CC(C)=C1C=O JFRPWJDOGGLZFS-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
206010003225 Arteriospasm coronary Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000006561 Cluster Headache Diseases 0.000 description 1
208000003890 Coronary Vasospasm Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
102000015433 Prostaglandin Receptors Human genes 0.000 description 1
108010050183 Prostaglandin Receptors Proteins 0.000 description 1
GTOOEBOQIWUXBA-UHFFFAOYSA-N S(=O)(Cl)Cl.CC1=C(CCl)C(=CC(=C1)C(C)C)C Chemical compound S(=O)(Cl)Cl.CC1=C(CCl)C(=CC(=C1)C(C)C)C GTOOEBOQIWUXBA-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
230000005792 cardiovascular activity Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
208000018912 cluster headache syndrome Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000011340 continuous therapy Methods 0.000 description 1
229910000365 copper sulfate Inorganic materials 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
201000011634 coronary artery vasospasm Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
150000001989 diazonium salts Chemical class 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
229960004704 dihydroergotamine Drugs 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
229960004943 ergotamine Drugs 0.000 description 1
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 1
229950001476 idazoxan Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052987 metal hydride Inorganic materials 0.000 description 1
150000004681 metal hydrides Chemical class 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
ACYBVNYNIZTUIL-UHFFFAOYSA-N n'-benzylethane-1,2-diamine Chemical compound NCCNCC1=CC=CC=C1 ACYBVNYNIZTUIL-UHFFFAOYSA-N 0.000 description 1
KFIGICHILYTCJF-UHFFFAOYSA-N n'-methylethane-1,2-diamine Chemical compound CNCCN KFIGICHILYTCJF-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
229960001528 oxymetazoline Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
ZJPSLIRAITULFG-UHFFFAOYSA-N sodium 2-(4-tert-butylphenyl)acetonitrile cyanide Chemical compound [C-]#N.[Na+].C(C)(C)(C)C1=CC=C(C=C1)CC#N ZJPSLIRAITULFG-UHFFFAOYSA-N 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
230000028016 temperature homeostasis Effects 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 2246027 1998-08-27 1998-08-27 Derives de benzylamidine avec activite de fixation provenant des recepteurs de la serotonine Abandoned CA2246027A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2246027 CA2246027A1 (fr)	1998-08-27	1998-08-27	Derives de benzylamidine avec activite de fixation provenant des recepteurs de la serotonine

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2246027 CA2246027A1 (fr)	1998-08-27	1998-08-27	Derives de benzylamidine avec activite de fixation provenant des recepteurs de la serotonine

Publications (1)

Publication Number	Publication Date
CA2246027A1 true CA2246027A1 (fr)	2000-02-27

Family

ID=29409805

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2246027 Abandoned CA2246027A1 (fr)	1998-08-27	1998-08-27	Derives de benzylamidine avec activite de fixation provenant des recepteurs de la serotonine

Country Status (1)

Country	Link
CA (1)	CA2246027A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007085557A3 (fr) *	2006-01-27	2007-09-20	Hoffmann La Roche	Utilisation de 2-imidazole substitue de derives d'imidazoline
US7652055B2 (en)	2007-07-02	2010-01-26	Hoffman-La Roche Inc.	2-imidazolines
US7812047B2 (en)	2007-07-03	2010-10-12	Hoffman-La Roche Inc.	4-imidazolines
US7834044B2 (en)	2006-11-02	2010-11-16	Hoffman-Laroche Inc.	Substituted-2-imidazoles
US7858652B2 (en)	2006-11-16	2010-12-28	Hoffmann-La Roche Inc.	Substituted 4-imidazoles
US7858653B2 (en)	2006-12-13	2010-12-28	Hoffman-La Roche Inc.	2-imidazoles
US7902238B2 (en)	2007-02-15	2011-03-08	Hoffmann-La Roche Inc.	2-aminooxazolines as TAAR1 ligands
US8008305B2 (en)	2007-08-03	2011-08-30	Hoffmann-La Roche Inc.	TAAR1 ligands
US8242153B2 (en)	2008-07-24	2012-08-14	Hoffmann-La Roche Inc.	4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en)	2009-11-11	2013-01-15	Hoffmann-La Roche Inc.	Oxazoline derivatives
US8389507B2 (en)	2007-07-27	2013-03-05	Hoffmann-La Roche Inc.	2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands
US8399463B2 (en)	2006-12-18	2013-03-19	Hoffmann-La Roche Inc.	Imidazole derivatives
US8586617B2 (en)	2006-10-19	2013-11-19	Hoffmann-La Roche Inc.	Aminomethyl-4-imidazoles
US8604061B2 (en)	2007-02-02	2013-12-10	Hoffmann-La Roche Inc.	2-aminooxazolines as TAAR1 ligands
US9452980B2 (en)	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
US10508107B2 (en)	2016-03-17	2019-12-17	Hoffmann-La Roche Inc.	Morpholine derivative
JP2023541375A (ja) *	2020-08-27	2023-10-02	キュラセンセラピューティクスインコーポレイテッド	α１Ａ－アドレナリン受容体アゴニスト及び使用方法

1998
- 1998-08-27 CA CA 2246027 patent/CA2246027A1/fr not_active Abandoned

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007085557A3 (fr) *	2006-01-27	2007-09-20	Hoffmann La Roche	Utilisation de 2-imidazole substitue de derives d'imidazoline
US7875645B2 (en)	2006-01-27	2011-01-25	Hoffman-La Roche Inc.	Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
US8586617B2 (en)	2006-10-19	2013-11-19	Hoffmann-La Roche Inc.	Aminomethyl-4-imidazoles
US7834044B2 (en)	2006-11-02	2010-11-16	Hoffman-Laroche Inc.	Substituted-2-imidazoles
US7858652B2 (en)	2006-11-16	2010-12-28	Hoffmann-La Roche Inc.	Substituted 4-imidazoles
US7858653B2 (en)	2006-12-13	2010-12-28	Hoffman-La Roche Inc.	2-imidazoles
US8399463B2 (en)	2006-12-18	2013-03-19	Hoffmann-La Roche Inc.	Imidazole derivatives
US8604061B2 (en)	2007-02-02	2013-12-10	Hoffmann-La Roche Inc.	2-aminooxazolines as TAAR1 ligands
US7902238B2 (en)	2007-02-15	2011-03-08	Hoffmann-La Roche Inc.	2-aminooxazolines as TAAR1 ligands
US7652055B2 (en)	2007-07-02	2010-01-26	Hoffman-La Roche Inc.	2-imidazolines
US7812047B2 (en)	2007-07-03	2010-10-12	Hoffman-La Roche Inc.	4-imidazolines
US8389507B2 (en)	2007-07-27	2013-03-05	Hoffmann-La Roche Inc.	2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands
US8008305B2 (en)	2007-08-03	2011-08-30	Hoffmann-La Roche Inc.	TAAR1 ligands
US8729113B2 (en)	2008-07-24	2014-05-20	Hoffmann-La Roche Inc.	4,5-dihydro-oxazol-2yl derivatives
US8242153B2 (en)	2008-07-24	2012-08-14	Hoffmann-La Roche Inc.	4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en)	2009-11-11	2013-01-15	Hoffmann-La Roche Inc.	Oxazoline derivatives
US9452980B2 (en)	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
US10508107B2 (en)	2016-03-17	2019-12-17	Hoffmann-La Roche Inc.	Morpholine derivative
JP2023541375A (ja) *	2020-08-27	2023-10-02	キュラセンセラピューティクスインコーポレイテッド	α１Ａ－アドレナリン受容体アゴニスト及び使用方法
EP4204404A4 (fr) *	2020-08-27	2024-12-25	Curasen Therapeutics, Inc.	Agonistes du récepteur alpha1a-adrénergique et méthodes d'utilisation

Legal Events

Date	Code	Title	Description
2004-08-27	FZDE	Dead

Publication	Publication Date	Title
US5969137A (en)	1999-10-19	Benzylamidine derivatives with serotonin receptor binding activity
CA2246027A1 (fr)	2000-02-27	Derives de benzylamidine avec activite de fixation provenant des recepteurs de la serotonine
AU600769B2 (en)	1990-08-23	Tetrahydronaphthalene derivatives
PL177604B1 (pl)	1999-12-31	Pochodne 5-aryloindolu
HU196971B (en)	1989-02-28	Process for producing new benzimidazol derivatives and pharmaceutical compositions containing them
EP0482939A1 (fr)	1992-04-29	Dérive d'isoquinolinone
EP1490361B1 (fr)	2007-10-03	Composes polycycliques comme antagonistes puissants des recepteurs alpha2-adrenergiques
HUP0204458A2 (hu)	2003-04-28	Alfa-2-antagonista hatású kinolinszármazékok és ezeket tartalmazó gyógyszerkészítmények
HU199791B (en)	1990-03-28	Process for producing carboxamides comprising indolyl and indazolyl group
HUP0103691A2 (hu)	2002-02-28	Pirido[1,2a]pirazin-származékok alkalmazása Parkinson-kór, az ADHD és mikroadenómák kezelésében és ezeket tartalmazó gyógyszerkészítmények
US20020119989A1 (en)	2002-08-29	Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
JPH0231077B2 (fr)	1990-07-11
JP2004509954A (ja)	2004-04-02	治療に用いるための環化したベンズアミドニューロキニンアンタゴニスト
US5925665A (en)	1999-07-20	Imidazoline compounds
CA2557650A1 (fr)	2005-09-22	Modulateurs de canal ionique
US5504101A (en)	1996-04-02	5-HT-1D receptor ligands
US6288101B1 (en)	2001-09-11	Imidazoles with serotonin receptor binding activity
WO2008157407A2 (fr)	2008-12-24	Compositions et procédés pour traiter la leucémie
AU2005231123A1 (en)	2005-10-20	Ion channel modulators
WO2005121152A1 (fr)	2005-12-22	Derives triazole substitues utilises en tant qu'antagonistes de l'oxytocine
WO2008075162A2 (fr)	2008-06-26	Composés pour le traitement d'un dysfonctionnement sexuel
EP0092328B1 (fr)	1987-05-20	Dérivés d'imidazoline
HU202229B (en)	1991-02-28	Process for producing new pyrazolyl- and indazolyl-pyridin-amine derivatives and pharmaceutical compositions containing them
CA3213396A1 (fr)	2022-09-15	Compositions et methodes de traitement de l'anemie associee a un trouble ribosomique
EP1863795B1 (fr)	2008-10-29	Derives de triazole substitues en tant qu'antagonistes d'oxytocine